Patent application number | Description | Published |
20090005370 | ISOXAZOLE-IMIDAZOLE DERIVATIVES - The present invention is concerned isoxazole-imidazole derivatives having affinity and selectivity for GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use for enhancing cognition or for the treatment of cognitive disorders like Alzheimer's disease. In particular, the present invention is concerned with aryl-isoxazol-4-yl-imidazole derivatives of formula I | 01-01-2009 |
20090143371 | ISOXAZOLE-PYRIDINE DERIVATIVES - The present invention is concerned with isoxazole-pyridine derivatives of formula I | 06-04-2009 |
20090143385 | ISOXAZOLO-PYRIDAZINE DERIVATIVES - The invention relates to isoxazolo-pyridazine compounds, in particular those of formula I as described above and to a pharmaceutically acceptable salts thereof, having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the treatment of cognitive disorders like Alzheimer's disease. | 06-04-2009 |
20090143407 | ISOXAZOLO-PYRAZINE DERIVATIVES - The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of present invention are inverse agonists of GABA A α5. The invention also relates to methods for enhancing cognition and for treating cognitive disorders like Alzheimer's disease. | 06-04-2009 |
20090197875 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES - The present invention is concerned with isoxazol-4-yl-oxadiazole derivatives of formula | 08-06-2009 |
20100041886 | ISOXAZOLO-PYRAZINE DERIVATIVES - The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of present invention are inverse agonists of GABA A α5. The invention also relates to methods for enhancing cognition and for treating cognitive disorders like Alzheimer's disease. | 02-18-2010 |
20100210651 | ISOXAZOLE-ISOXAZOLES AND ISOXAZOLE-ISOTHIAZOLES - The present invention is concerned with isoxazole-isoxazoles and isoxazole-isothiazoles of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as cognitive enhancers or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease. | 08-19-2010 |
20100216845 | ISOXAZOLES / O-PYRIDINES WITH ETHYL AND ETHENYL LINKER - The present invention is concerned with novel isoxazole-pyridines of formula I | 08-26-2010 |
20100280019 | ISOXAZOLES - The present invention is concerned with novel isoxazole derivatives of formula I | 11-04-2010 |
20100280020 | ISOXAZOLES - The present invention is concerned with novel isoxazole derivatives of formula I | 11-04-2010 |
20100286115 | PYRAZOLES - The present invention is concerned with isoxazole-pyrazoles of formula I, having affinity and selectivity for GABA A a5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutics. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease. | 11-11-2010 |
20100286116 | THIAZOLES - The present invention is concerned with isoxazole-thiazole derivatives of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease. | 11-11-2010 |
20100286117 | PYRIDINES - The present invention is concerned with novel isoxazoles of formula I | 11-11-2010 |
20100286132 | PYRIDINES - The present invention is concerned with isoxazole-pyridines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as pharmaceuticals. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease. | 11-11-2010 |
20100286159 | PYRIDAZINES - The present invention is concerned with isoxazole-pyridazines of formula I, having affinity and selectivity for GABA A α5 receptor, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease. | 11-11-2010 |
20110190269 | GAMMA SECRETASE MODULATORS - The invention relates to compounds of formula | 08-04-2011 |
20110201605 | HETEROARYL SUBSTITUTED PIPERIDINES - The invention relates to compounds of formula | 08-18-2011 |
20120115839 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS - The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain. | 05-10-2012 |
20120115844 | NOVEL TRIAZOLE COMPOUNDS I - The present invention is concerned with novel triazole compounds of formula (I) | 05-10-2012 |
20120115868 | NOVEL TRIAZOLE COMPOUNDS II - The present invention is concerned with novel triazole compounds of formula (I) | 05-10-2012 |
20120149675 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS - The present invention is concerned with novel 1,2,3-triazole-imidazole compounds of formula (I) | 06-14-2012 |
20120184538 | ISOXAZOLO-PYRIDINE DERIVATIVES - The present invention is concerned with isoxazole-pyridine derivatives of formula I | 07-19-2012 |
20120225884 | BRIDGED PIPERIDINE DERIVATIVES - The present invention relates to compounds of formula I | 09-06-2012 |
20120238548 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS - The present invention relates to 1,4-Oxazepines of formula I | 09-20-2012 |
20130102778 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS - The present invention relates to a process for the preparation of a compound of formula (I) | 04-25-2013 |
20130172329 | NOVEL SOLID FORMS - The instant invention relates to novel solid forms of the compound of formula (I) | 07-04-2013 |
20130274467 | ISOXAZOLO-PYRIDINE DERIVATIVES - The present invention is concerned with isoxazole-pyridine derivatives of formula I | 10-17-2013 |
20130274468 | ISOXAZOLO-PYRIDINE DERIVATIVES - The present invention is concerned with isoxazole-pyridine derivatives of formula I | 10-17-2013 |
20130274469 | ISOXAZOLO-PYRIDINE DERIVATIVES - The present invention is concerned with isoxazole-pyridine derivatives of formula I | 10-17-2013 |
20130281690 | ISOXAZOLO-PYRIDINE DERIVATIVES - The present invention is concerned with isoxazole-pyridine derivatives of formula I | 10-24-2013 |
20140329806 | NOVEL SOLID FORMS - The instant invention relates to novel solid forms of the compound of formula (I) | 11-06-2014 |
20140343046 | USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS - The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain. | 11-20-2014 |